AVD-YOLOv5: a new lightweight network architecture for high-speed aortic valve detection from a new and large echocardiography dataset.

Heart disease detection is currently gaining widespread attention as a means to enhance the accuracy of cardiologists' diagnoses from cardiac images and reduce diagnosis time. Although high-resolution computed tomography (CT) images are typically favored for heart disease detection, the drawbacks of cost and radiation exposure to patients necessitate alternative approaches. In this context, utilizing ultrasound images becomes pivotal to mitigate radiation risks and maintain cost-effectiveness. In this paper, we propose a novel lightweight model, AVD-YOLOv5, designed for automated aortic valve detection on echocardiography images. This model incorporates several enhancements to the YOLOv5 architecture. Notably, the depth-wise separable convolution significantly contributes to the model's lightweight design by reducing the number of parameters while maintaining precision. We have also created a new and larger dataset comprising 260 echocardiography images specifically for aortic valve detection. Experimental results indicate that the precision value of the modified ADV-YOLOv5 model stands at 94.3%, with a recall value of 86.8%. The model also demonstrates a notable 67% reduction in inference time compared to the original YOLOv5 model. Although there is a marginal reduction in precision by 0.94%, the model's efficiency is significantly increased. The proposed system can be used by cardiologists for more efficient and reliable diagnosis.

Simvastatin impairs spatial memory in rats at a specific dose level.

Statins, inhibitors of cholesterol synthesis, are used to prevent cardiovascular complications. Moreover, statins have been shown to influence some cognitive functions. The modulating effects of simvastatin, one member of the statin family, on memory-related neurotransmitters and neuronal structures have also been reported. We aimed to investigate the behavioral effects of long-term simvastatin application on daily activity, psychomotor performance and spatial memory using Sprague-Dawley rats. Simvastatin (10 or 30 mg/kg/day) was administered orally to rats, in parallel with a vehicle-treated group. Daily activity test results of both simvastatin groups were found similar to the vehicle group after five weeks of simvastatin or vehicle application. Psychomotor performance was measured with the rotarod test. After 6 weeks of simvastatin or vehicle application, the vehicle-treated group stayed on the rotarod device for a shorter time compared with both simvastatin-treated groups. Spatial memory was evaluated by the Barnes maze test. Four weeks of 10 mg/kg/day simvastatin application led to poorer scores on spatial memory compared to the vehicle group, but surprisingly, this effect was not seen in the 30 mg/kg/day group. Our results revealed that simvastatin administration had no significant effect on daily activity. Psychomotor performance test results suggested that simvastatin alters psychomotor behavior at higher nervous system levels. Spatial memory test results indicate that long-term simvastatin usage impairs spatial memory only at 10 mg/kg/day dose.

Fluvastatin alters psychomotor performance and daily activity but not the spatial memory in rats.

Statins, inhibitors of cholesterol synthesis for treating dyslipidemia and preventing cardiovascular complications, have been shown to alter central nervous system functions. Our aim was to investigate the effects of the fluvastatin, a member of statin family, on psychomotor performance, daily activity and spatial memory. Sprague-Dawley rats were treated with fluvastatin (n = 8) or placebo as a control (n = 11) regardless of sex. Fluvastatin (7.5 mg/kg) was administered orally once a day for four weeks, while the control group was administered only placebo. Psychomotor performance was measured by rotarod tests. No significant difference was observed in the fluvastatin group over the course of weeks, but the control group preferred to stay on the device shorter times (p < 0.05). For the first three weeks of the drug administration there was a statistical difference between the groups, however no difference was found after the 4th week. There was no difference in the Barnes maze spatial memory test between the groups and also within the groups over the course of time. Daily activity tests revealed that stereotypical and vertical movements of the fluvastatin group were significantly less than the control group in all four weeks. Ambulatory movements and the distances taken by the fluvastatin group were decreased significantly over the course of time (p < 0.005 and p < 0.001, respectively), but the control group did not reveal any significant change. Our results suggest that fluvastatin altered psychomotor performance and daily activity in rats, but it did not affect the spatial memory. These behavioral changes might be associated with alterations in the composition of the brain lipids caused by fluvastatin.